Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Thalidomide"" wg kryterium: Temat


Tytuł :
Multidisciplinary Management of the Adverse Effects of Apremilast.
Autorzy :
Daudén Tello E; Servicio de Dermatología, Hospital Universitario La Princesa, Madrid, España. Electronic address: .
Alonso Suárez J; Servicio de Dermatología, Hospital Universitario Virgen de la Victoria, Málaga, España.
Beltrán Catalán E; Servicio de Reumatología, Hospital Parc Salut del Mar, Barcelona, España.
Blasco Maldonado C; Unidad de Enfermería, Servicio de Dermatología, Hospital Universitario Puerta de Hierro, Madrid, España.
Herrero Manso MC; Unidad de Enfermería, Servicio de Reumatología, Hospital Universitario 12 de Octubre, Madrid, España.
Jiménez Morales A; Servicio de Farmacia, Hospital Universitario Virgen de las Nieves, Granada, España.
Marín-Jiménez I; Unidad de EII-CEIMI-Servicio de Aparato Digestivo, Hospital Gregorio Marañón, Madrid, España.
Martín-Arranz MD; Servicio de Aparato Digestivo, Hospital Universitario La Paz; Grupo de Inmunidad Innata, Instituto de Investigación IdiPaz, Madrid, España.
García-Merino A; Servicio de Neurología, Hospital Universitario Puerta de Hierro, Madrid, España.
Porta Etessam J; Servicio de Neurología, Hospital Clínico San Carlos, Madrid, España.
Rodríguez-Sagrado MA; Servicio de Farmacia, Hospital Universitario Ramón y Cajal, Madrid, España.
Rosas Gómez de Salazar J; Sección de Reumatología, Hospital Marina Baixa, Villajoyosa, Alicante, España.
Trujillo Martín E; Servicio Reumatología, Hospital Universitario de Gran Canaria, Las Palmas de Gran Canaria, España.
Salgado-Boquete L; Servicio de Dermatología, Complejo Hospitalario Universitario, Pontevedra, España.
Pokaż więcej
Transliterated Title :
Manejo de los efectos adversos de apremilast desde un abordaje multidisciplinar.
Źródło :
Actas dermo-sifiliograficas [Actas Dermosifiliogr] 2021 Feb; Vol. 112 (2), pp. 134-141. Date of Electronic Publication: 2020 Sep 07.
Typ publikacji :
Journal Article
MeSH Terms :
Diarrhea/*chemically induced
Headache/*chemically induced
Nausea/*chemically induced
Phosphodiesterase 4 Inhibitors/*adverse effects
Thalidomide/*analogs & derivatives
Combined Modality Therapy ; Diarrhea/diet therapy ; Diarrhea/drug therapy ; Diarrhea/physiopathology ; Disease Management ; Headache/drug therapy ; Headache/physiopathology ; Headache/prevention & control ; Humans ; Nausea/diet therapy ; Nausea/drug therapy ; Nausea/physiopathology ; Patient Care Team ; Phosphodiesterase 4 Inhibitors/therapeutic use ; Practice Guidelines as Topic ; Psoriasis/drug therapy ; Thalidomide/adverse effects ; Thalidomide/therapeutic use
Czasopismo naukowe
Tytuł :
Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents.
Autorzy :
El-Zahabi MA; Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt. Electronic address: .
Sakr H; Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt.
El-Adl K; Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Heliopolis University for Sustainable Development, Cairo, Egypt.
Zayed M; Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt; Pharmaceutical Sciences Department, Fakeeh College for Medical Sciences, Jeddah 21461, Saudi Arabia.
Abdelraheem AS; Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt.
Eissa SI; Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Nasser City, Egypt.
Elkady H; Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Heliopolis University for Sustainable Development, Cairo, Egypt.
Eissa IH; Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt. Electronic address: .
Pokaż więcej
Źródło :
Bioorganic chemistry [Bioorg Chem] 2020 Nov; Vol. 104, pp. 104218. Date of Electronic Publication: 2020 Sep 01.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Design*
Antineoplastic Agents/*pharmacology
Enzyme Inhibitors/*pharmacology
Immunologic Factors/*pharmacology
Thalidomide/*pharmacology
Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Caspase 8/metabolism ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Enzyme Inhibitors/chemical synthesis ; Enzyme Inhibitors/chemistry ; Humans ; Immunologic Factors/chemical synthesis ; Immunologic Factors/chemistry ; Molecular Structure ; NF-kappa B/antagonists & inhibitors ; NF-kappa B/metabolism ; Structure-Activity Relationship ; Thalidomide/chemical synthesis ; Thalidomide/chemistry ; Tumor Necrosis Factor-alpha/antagonists & inhibitors ; Tumor Necrosis Factor-alpha/metabolism ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Vascular Endothelial Growth Factor A/metabolism
Czasopismo naukowe
Tytuł :
Discovery of First-In-Class Potent and Selective Tropomyosin Receptor Kinase Degraders.
Autorzy :
Chen L; Cullgen (Shanghai), Inc., 230 ChuanHong Road, Building 6, Chuansha, Pudong New Area, Shanghai 201202, People's Republic of China.
Chen Y; Cullgen (Shanghai), Inc., 230 ChuanHong Road, Building 6, Chuansha, Pudong New Area, Shanghai 201202, People's Republic of China.
Zhang C; Cullgen (Shanghai), Inc., 230 ChuanHong Road, Building 6, Chuansha, Pudong New Area, Shanghai 201202, People's Republic of China.
Jiao B; Cullgen (Shanghai), Inc., 230 ChuanHong Road, Building 6, Chuansha, Pudong New Area, Shanghai 201202, People's Republic of China.
Liang S; Cullgen (Shanghai), Inc., 230 ChuanHong Road, Building 6, Chuansha, Pudong New Area, Shanghai 201202, People's Republic of China.
Tan Q; Cullgen (Shanghai), Inc., 230 ChuanHong Road, Building 6, Chuansha, Pudong New Area, Shanghai 201202, People's Republic of China.
Chai H; Cullgen (Shanghai), Inc., 230 ChuanHong Road, Building 6, Chuansha, Pudong New Area, Shanghai 201202, People's Republic of China.
Yu W; Cullgen (Shanghai), Inc., 230 ChuanHong Road, Building 6, Chuansha, Pudong New Area, Shanghai 201202, People's Republic of China.
Qian Y; Cullgen (Shanghai), Inc., 230 ChuanHong Road, Building 6, Chuansha, Pudong New Area, Shanghai 201202, People's Republic of China.
Yang H; Cullgen (Shanghai), Inc., 230 ChuanHong Road, Building 6, Chuansha, Pudong New Area, Shanghai 201202, People's Republic of China.
Yao W; Cullgen (Shanghai), Inc., 230 ChuanHong Road, Building 6, Chuansha, Pudong New Area, Shanghai 201202, People's Republic of China.
Yu J; Cullgen (Shanghai), Inc., 230 ChuanHong Road, Building 6, Chuansha, Pudong New Area, Shanghai 201202, People's Republic of China.
Luo Y; Cullgen Inc., 12671 High Bluff Drive Suite 130, San Diego, California 92130, United States.
Plewe M; Cullgen Inc., 12671 High Bluff Drive Suite 130, San Diego, California 92130, United States.
Wang J; Cullgen Inc., 12671 High Bluff Drive Suite 130, San Diego, California 92130, United States.; Cullgen (Shanghai), Inc., 230 ChuanHong Road, Building 6, Chuansha, Pudong New Area, Shanghai 201202, People's Republic of China.
Han XR; Cullgen Inc., 12671 High Bluff Drive Suite 130, San Diego, California 92130, United States.; Cullgen (Shanghai), Inc., 230 ChuanHong Road, Building 6, Chuansha, Pudong New Area, Shanghai 201202, People's Republic of China.
Liu J; Cullgen Inc., 12671 High Bluff Drive Suite 130, San Diego, California 92130, United States.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2020 Dec 10; Vol. 63 (23), pp. 14562-14575. Date of Electronic Publication: 2020 Oct 15.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Protein Kinase Inhibitors/*pharmacology
Pyridazines/*pharmacology
Receptor Protein-Tyrosine Kinases/*antagonists & inhibitors
Thalidomide/*analogs & derivatives
Thalidomide/*pharmacology
Animals ; Cell Line, Tumor ; Down-Regulation/drug effects ; Drug Design ; Drug Discovery ; Humans ; Male ; Mice, Inbred ICR ; Molecular Structure ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/pharmacokinetics ; Proteolysis/drug effects ; Pyridazines/chemical synthesis ; Pyridazines/pharmacokinetics ; Receptor Protein-Tyrosine Kinases/metabolism ; Receptor, trkA/antagonists & inhibitors ; Receptor, trkA/metabolism ; Receptor, trkB/antagonists & inhibitors ; Receptor, trkB/metabolism ; Receptor, trkC/antagonists & inhibitors ; Receptor, trkC/metabolism ; Structure-Activity Relationship ; Thalidomide/pharmacokinetics ; Ubiquitin-Protein Ligases/metabolism
Czasopismo naukowe
Tytuł :
Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen.
Autorzy :
Szudy-Szczyrek A; Chair and Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081, Lublin, Poland. .
Mlak R; Chair and Department of Human Physiology, Medical University of Lublin, 20-080, Lublin, Poland.
Mielnik M; Chair and Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081, Lublin, Poland.
Szczyrek M; Chair and Department of Pneumology, Oncology and Allergology, Medical University of Lublin, 20-090, Lublin, Poland.
Nowaczyńska A; Chair and Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081, Lublin, Poland.
Homa-Mlak I; Chair and Department of Human Physiology, Medical University of Lublin, 20-080, Lublin, Poland.
Zmorzyński S; Department of Cancer Genetics with Cytogenetics Laboratory, Medical University of Lublin, 20-080, Lublin, Poland.
Kuśmierczuk K; Chair and Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081, Lublin, Poland.
Sompor J; Department of Traumatology and Emergency Medicine, Medical University of Lublin, 20-081, Lublin, Poland.
Filip A; Department of Cancer Genetics with Cytogenetics Laboratory, Medical University of Lublin, 20-080, Lublin, Poland.
Małecka-Massalska T; Chair and Department of Human Physiology, Medical University of Lublin, 20-080, Lublin, Poland.
Hus M; Chair and Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081, Lublin, Poland.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Dec; Vol. 99 (12), pp. 2881-2891. Date of Electronic Publication: 2020 May 26.
Typ publikacji :
Journal Article
MeSH Terms :
Blood Platelets/*metabolism
Lymphocytes/*metabolism
Multiple Myeloma/*blood
Multiple Myeloma/*drug therapy
Neutrophils/*metabolism
Thalidomide/*therapeutic use
Aged ; Blood Platelets/drug effects ; Female ; Follow-Up Studies ; Humans ; Immunosuppressive Agents/therapeutic use ; Lymphocyte Count/methods ; Lymphocytes/drug effects ; Male ; Middle Aged ; Multiple Myeloma/mortality ; Neutrophils/drug effects ; Platelet Count/methods ; Prognosis ; Survival Rate/trends ; Thalidomide/pharmacology ; Treatment Outcome
Czasopismo naukowe
Tytuł :
COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain.
Autorzy :
Queiro Silva R; Rheumatology Division, Hospital Universitario Central de Asturias, Oviedo, Spain.
Armesto S; Department of Dermatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
González Vela C; Department of Pathology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Naharro Fernández C; Department of Dermatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
González-Gay MA; Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Pokaż więcej
Źródło :
Dermatologic therapy [Dermatol Ther] 2020 Nov; Vol. 33 (6), pp. e13961. Date of Electronic Publication: 2020 Jul 27.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Arthritis, Psoriatic/*drug therapy
COVID-19/*complications
Immunosuppressive Agents/*administration & dosage
Psoriasis/*drug therapy
Thalidomide/*analogs & derivatives
Adult ; Anti-Inflammatory Agents, Non-Steroidal/administration & dosage ; Anti-Inflammatory Agents, Non-Steroidal/adverse effects ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Antirheumatic Agents/administration & dosage ; Antirheumatic Agents/adverse effects ; Female ; Humans ; Immunosuppressive Agents/adverse effects ; Infliximab/administration & dosage ; Infliximab/adverse effects ; Male ; Middle Aged ; Spain ; Thalidomide/administration & dosage ; Thalidomide/adverse effects
Czasopismo naukowe
Tytuł :
Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.
Autorzy :
Chu TH; Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, Jeollanamdo, Republic of Korea.
Vo MC; Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, Jeollanamdo, Republic of Korea.; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, 322 Seoyangro, Hwasun, Jeollanamdo, 519-763, Republic of Korea.
Park HS; Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, Jeollanamdo, Republic of Korea.
Lakshmi TJ; Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, Jeollanamdo, Republic of Korea.
Jung SH; Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, Jeollanamdo, Republic of Korea. .; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, 322 Seoyangro, Hwasun, Jeollanamdo, 519-763, Republic of Korea. .
Kim HJ; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, 322 Seoyangro, Hwasun, Jeollanamdo, 519-763, Republic of Korea.
Lee JJ; Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, Jeollanamdo, Republic of Korea. .; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, 322 Seoyangro, Hwasun, Jeollanamdo, 519-763, Republic of Korea. .; Vaxcell-Bio Therapeutics, Hwasun, Jeollanamdo, Republic of Korea. .
Pokaż więcej
Źródło :
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2021 Jan; Vol. 70 (1), pp. 31-45. Date of Electronic Publication: 2020 Jul 04.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
B7-H1 Antigen/*antagonists & inhibitors
Dendritic Cells/*immunology
Immune Checkpoint Inhibitors/*pharmacology
Multiple Myeloma/*drug therapy
Multiple Myeloma/*therapy
Thalidomide/*analogs & derivatives
Animals ; Cell Proliferation/drug effects ; Cell- and Tissue-Based Therapy/methods ; Cells, Cultured ; Chemotherapy, Adjuvant/methods ; Drug Evaluation, Preclinical/methods ; Female ; Immunosuppressive Agents/pharmacology ; Immunotherapy/methods ; Mice ; Mice, Inbred BALB C ; Multiple Myeloma/immunology ; Spleen/drug effects ; Spleen/immunology ; T-Lymphocytes, Cytotoxic/drug effects ; T-Lymphocytes, Cytotoxic/immunology ; Thalidomide/pharmacology ; Vaccination/methods
Czasopismo naukowe
Tytuł :
Pomalidomide and dexamethasone in myelomatous pleural effusion.
Autorzy :
Comba IY; Department of Internal Medicine, University of Central Florida College of Medicine, Orlando, Florida, USA .
Chahin A; Department of Internal Medicine, University of Central Florida College of Medicine, Orlando, Florida, USA.
Taj H; Department of Internal Medicine, University of Central Florida College of Medicine, Orlando, Florida, USA.
Carilli A; Division of Hematology and Oncology, Orlando VA Medical Center, Orlando, Florida, USA.
Pokaż więcej
Źródło :
BMJ case reports [BMJ Case Rep] 2020 Dec 10; Vol. 13 (12). Date of Electronic Publication: 2020 Dec 10.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Dexamethasone/*therapeutic use
Multiple Myeloma/*complications
Pleural Effusion, Malignant/*therapy
Thalidomide/*analogs & derivatives
Drainage ; Dyspnea/etiology ; Humans ; Male ; Middle Aged ; Plasma Cells/pathology ; Pleural Effusion, Malignant/diagnostic imaging ; Radiography, Thoracic ; Thalidomide/therapeutic use ; Thoracentesis ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma.
Autorzy :
Kuwahara-Ota S; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Shimura Y; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Steinebach C; Department of Pharmaceutical & Medicinal Chemistry, University of Bonn, Pharmaceutical Institute, Bonn, Germany.
Isa R; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Yamaguchi J; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Nishiyama D; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Fujibayashi Y; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Takimoto-Shimomura T; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Mizuno Y; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Matsumura-Kimoto Y; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Tsukamoto T; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Chinen Y; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.; Department of Hematology, Fukuchiyama City Hospital, Kyoto, Japan.
Kobayashi T; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Horiike S; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Taniwaki M; Center for Molecular Diagnostics and Therapeutics, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Gütschow M; Department of Pharmaceutical & Medicinal Chemistry, University of Bonn, Pharmaceutical Institute, Bonn, Germany.
Kuroda J; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2020 Dec; Vol. 191 (5), pp. 784-795. Date of Electronic Publication: 2020 Jun 19.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Lenalidomide/*pharmacology
Multiple Myeloma/*immunology
Myeloid-Derived Suppressor Cells/*immunology
Thalidomide/*analogs & derivatives
Cell Line, Tumor ; Chemokine CCL5/immunology ; Coculture Techniques ; Humans ; Interferon Regulatory Factors/immunology ; Intramolecular Oxidoreductases/immunology ; Macrophage Migration-Inhibitory Factors/immunology ; Multiple Myeloma/drug therapy ; Multiple Myeloma/pathology ; Myeloid-Derived Suppressor Cells/pathology ; Neoplasm Proteins/immunology ; Thalidomide/pharmacology
Czasopismo naukowe
Tytuł :
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.
Autorzy :
Siegel DS; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA. .
Schiller GJ; David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
Samaras C; Cleveland Clinic, Cleveland, OH, USA.
Sebag M; McGill University Health Centre, Montreal, QC, Canada.
Berdeja J; Sarah Cannon Research Institute, Nashville, TN, USA.
Ganguly S; The University of Kansas Cancer Center, Fairway, KS, USA.
Matous J; Colorado Blood Cancer Institute, Denver, CO, USA.
Song K; Vancouver General Hospital, Vancouver, BC, Canada.
Seet CS; David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
Talamo G; Penn State Hershey Cancer Institute, Hershey, PA, USA.
Acosta-Rivera M; Fundación de Investigación, San Juan, PR, USA.
Bar M; Stamford Hospital, Stamford, CT, USA.
Quick D; Joe Arrington Cancer Research and Treatment Center, Lubbock, TX, USA.
Anz B; Tennessee Oncology, Chattanooga, TN, USA.
Fonseca G; Florida Cancer Specialists, St. Petersburg, FL, USA.
Reece D; Princess Margaret Cancer Centre, Toronto, ON, Canada.
Pierceall WE; Bristol-Myers Squibb, Summit, NJ, USA.
Chung W; Bristol-Myers Squibb, Summit, NJ, USA.
Zafar F; Bristol-Myers Squibb, Summit, NJ, USA.
Agarwal A; Bristol-Myers Squibb, Summit, NJ, USA.
Bahlis NJ; Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada.
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2020 Dec; Vol. 34 (12), pp. 3286-3297. Date of Electronic Publication: 2020 May 06.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Dexamethasone/*therapeutic use
Lenalidomide/*therapeutic use
Multiple Myeloma/*drug therapy
Neoplasm Recurrence, Local/*drug therapy
Thalidomide/*analogs & derivatives
Aged ; Female ; Humans ; Male ; Progression-Free Survival ; Thalidomide/therapeutic use
Czasopismo naukowe
Tytuł :
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Autorzy :
Tacchetti P; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy.
Pantani L; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy.
Patriarca F; Clinical Hematology and Bone Marrow Transplant Centre, S Maria della Misericordia University Hospital, DAME, University of Udine, Udine, Italy.
Petrucci MT; Hematology Unit, and Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Zamagni E; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy.
Dozza L; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy.
Galli M; Hematology and Bone Marrow Transplant Unit, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
Di Raimondo F; Division of Hematology, Azienda Ospedaliero-Universitaria Policlinico, Department of Surgery and Medical Specialties, University of Catania, Catania, Italy.
Crippa C; Unità Operativa Complessa di Ematologia, Spedali Civili Brescia, Brescia, Italy.
Boccadoro M; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Cittàdella Salute e della Scienza, Turin, Italy.
Barbato S; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy.
Tosi P; Unità Operativa, Ematologia, Ospedale Infermi di Rimini, Rimini, Italy.
Narni F; Programma Trapianti Cellule Staminali Emopoietiche, Università di Modena e Reggio Emilia, Azienda Ospedaliero-Universitaria, Policlinico di Modena, Modena, Italy.
Montefusco V; Department of Hematology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Testoni N; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy.
Spadano A; Unità Operativa Complessa, Ematologia Clinica, Azienda Sanitaria Locale di Pescara, Pescara, Italy.
Terragna C; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy.
Pescosta N; Reparto di Ematologia e Centro Trapianto Midollo Osseo, Ospedale Centrale, Bolzano, Italy.
Marzocchi G; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy.
Cellini C; Unità Operativa Complessa Ematologia, Ospedale Santa Maria delle Croci, Ravenna, Italy.
Galieni P; Unità Operativa Complessa Ematologia e Terapia cellulare, Ospedale Costanzo e Giacomo Mazzoni, Ascoli Piceno, Italy.
Ronconi S; IRCCS, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy.
Gobbi M; Dipartimento di Medicina interna, Clinica Ematologica, Policlinico Ospedale San Martino, Genoa, Italy.
Catalano L; Unità Operativa Ematologia, Azienda Ospedaliero-Universitaria Federico II, Napoli, Italy.
Lazzaro A; Division of Hematology and Bone Marrow Transplant Center, Department of Oncology-Hematology, Guglielmo da Saliceto Hospital, Piacenza, Italy.
De Sabbata G; Struttura Complessa Ematologia, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.
Cangialosi C; Divisione di Ematologia ad indirizzo oncologico con Trapianto, Azienda Ospedali Riuniti 'Villa Sofia Cervello', Presidio Ospedaliero 'V Cervello', Palermo, Italy.
Ciambelli F; Struttura Complessa di Ematologia, Azienda Socio Sanitaria Territoriale della Valle Olona, Busto Arsizio, Italy.
Musto P; 'Aldo Moro' University School of Medicine, Unit of Hematology and Stem Cell Transplantation, AOUCPoliclinico, Bari, Italy; Unit of Hematology and Stem Cell Transplantation, Istituto di Ricovero e Cura a Carattere Scientifico Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy.
Elice F; Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy.
Cavo M; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy. Electronic address: .
Pokaż więcej
Corporate Authors :
GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto Italian Myeloma Network)
Źródło :
The Lancet. Haematology [Lancet Haematol] 2020 Dec; Vol. 7 (12), pp. e861-e873.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Bortezomib/*therapeutic use
Dexamethasone/*therapeutic use
Hematopoietic Stem Cell Transplantation/*methods
Multiple Myeloma/*drug therapy
Multiple Myeloma/*therapy
Thalidomide/*therapeutic use
Transplantation Conditioning/*methods
Transplantation, Autologous/*methods
Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Bortezomib/pharmacology ; Dexamethasone/pharmacology ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Multiple Myeloma/pathology ; Thalidomide/pharmacology ; Young Adult
Czasopismo naukowe
Tytuł :
Apremilast interferes with the TGFβ1-induced transition of human skin fibroblasts into profibrotic myofibroblasts: in vitro study.
Autorzy :
Cutolo M; Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa.
Soldano S; Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa.
Montagna P; Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa.
Martinelli G; Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa.
Tardito S; Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa.
Corallo C; Department of Medicine, Surgery and Neurosciences, Scleroderma Unit, University of Siena, Siena.
Giordano N; Department of Medicine, Surgery and Neurosciences, Scleroderma Unit, University of Siena, Siena.
Tavilla P; Department of Health Science, Unit of Dermatology, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy.
Cozzani E; Department of Health Science, Unit of Dermatology, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy.
Parodi A; Department of Health Science, Unit of Dermatology, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy.
Sulli A; Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa.
Pizzorni C; Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa.
Patane M; Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa.
Smith V; Department of Rheumatology, Ghent University Hospital.; Department of Internal Medicine, Ghent University.; Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium.
Paolino S; Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa.
Pokaż więcej
Źródło :
Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2020 Dec 01; Vol. 59 (12), pp. 3927-3938.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
Cell Differentiation/*drug effects
Fibroblasts/*drug effects
Myofibroblasts/*drug effects
Skin/*drug effects
Thalidomide/*analogs & derivatives
Transforming Growth Factor beta1/*pharmacology
Actins/metabolism ; Cells, Cultured ; Collagen Type I/metabolism ; Female ; Fibroblasts/physiology ; Fibronectins/metabolism ; Humans ; Middle Aged ; Myofibroblasts/physiology ; Skin/cytology ; Thalidomide/pharmacology ; Transforming Growth Factor beta1/antagonists & inhibitors
Czasopismo naukowe
Tytuł :
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.
Autorzy :
Roussel M; Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.
Moreau P; Hematology, University Hospital Hôtel-Dieu, Nantes, France.
Hebraud B; Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.
Laribi K; Centre Hospitalier, Le Mans, France.
Jaccard A; Centre Hospitalier Universitaire de Limoges, Limoges, France.
Dib M; Centre Hospitalier Régional Universitaire-Hôpital du Bocage, Angers, France.
Slama B; Centre Hospitalier H Duffaut, Avignon, France.
Dorvaux V; Hôpital de Mercy (Centre Hospitalier Régional Metz-Thionville), Metz, France.
Royer B; Hôpital St-Louis, Paris, France.
Frenzel L; Hôpital Necker, Paris, France.
Zweegman S; Amsterdam Universitair Medische Centra, Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, Netherlands.
Klein SK; Meander Medical Centre, Amersfoort, Netherlands.
Broijl A; Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Jie KS; Zuyderland MC, Sittard, Netherlands.
Wang J; Janssen Global Services, Raritan, NJ, USA.
Vanquickelberghe V; Janssen Research and Development, Beerse, Belgium.
de Boer C; Janssen Research and Development, Leiden, Netherlands.
Kampfenkel T; Janssen Research and Development, Leiden, Netherlands.
Gries KS; Janssen Global Services, Raritan, NJ, USA.
Fastenau J; Janssen Global Services, Raritan, NJ, USA.
Sonneveld P; Erasmus MC Cancer Institute, Rotterdam, Netherlands. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Haematology [Lancet Haematol] 2020 Dec; Vol. 7 (12), pp. e874-e883.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
Bortezomib/*therapeutic use
Dexamethasone/*therapeutic use
Multiple Myeloma/*drug therapy
Quality of Life/*psychology
Thalidomide/*therapeutic use
Antibodies, Monoclonal/pharmacology ; Antineoplastic Combined Chemotherapy Protocols ; Bortezomib/pharmacology ; Dexamethasone/pharmacology ; Female ; Humans ; Male ; Thalidomide/pharmacology
Czasopismo naukowe
Tytuł :
Outcome of COVID-19 in multiple myeloma patients in relation to treatment.
Autorzy :
Susek KH; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Gran C; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.; Department of Clinical Chemistry, Karolinska University Laboratory, Stockholm, Sweden.
Ljunggren HG; Center for Infectious Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Alici E; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.; Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
Nahi H; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.; Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
Pokaż więcej
Źródło :
European journal of haematology [Eur J Haematol] 2020 Dec; Vol. 105 (6), pp. 751-754. Date of Electronic Publication: 2020 Aug 18.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal/*adverse effects
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Coronavirus Infections/*diagnosis
Dexamethasone/*adverse effects
Lenalidomide/*adverse effects
Multiple Myeloma/*diagnosis
Pneumonia, Viral/*diagnosis
Thalidomide/*adverse effects
Antibodies, Monoclonal/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Betacoronavirus/pathogenicity ; COVID-19 ; Cohort Studies ; Coronavirus Infections/drug therapy ; Coronavirus Infections/immunology ; Coronavirus Infections/mortality ; Dexamethasone/administration & dosage ; Disease Progression ; Female ; Humans ; Immunomodulation ; Lenalidomide/administration & dosage ; Male ; Middle Aged ; Multiple Myeloma/drug therapy ; Multiple Myeloma/immunology ; Multiple Myeloma/mortality ; Pandemics ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/immunology ; Pneumonia, Viral/mortality ; Prognosis ; Remission Induction ; SARS-CoV-2 ; Severity of Illness Index ; Survival Analysis ; Thalidomide/administration & dosage ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Apremilast for the off-label treatment of lichenoid and interface dermatoses.
Autorzy :
Ravichandran S; Duke University School of Medicine, Duke University Medical Center, Durham, North Carolina.
Kheterpal MK; Department of Dermatology, Duke University Medical Center, Durham, North Carolina. Electronic address: .
Pokaż więcej
Źródło :
Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2020 Nov; Vol. 83 (5), pp. 1489-1491. Date of Electronic Publication: 2020 Jun 01.
Typ publikacji :
Journal Article
MeSH Terms :
Off-Label Use*
Lichenoid Eruptions/*drug therapy
Phosphodiesterase 4 Inhibitors/*therapeutic use
Thalidomide/*analogs & derivatives
Aged ; Female ; Humans ; Middle Aged ; Retrospective Studies ; Thalidomide/therapeutic use ; Young Adult
Czasopismo naukowe
Tytuł :
Functional characterization of a PROTAC directed against BRAF mutant V600E.
Autorzy :
Posternak G; Center for Molecular, Cell and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.; Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.; Department of Chemistry, University of Toronto, Toronto, Ontario, Canada.
Tang X; Center for Molecular, Cell and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Maisonneuve P; Center for Molecular, Cell and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Jin T; Institute for Research in Immunology and Cancer, Laboratory of Intracellular Signaling, Université de Montréal, Quebec, Montreal, Canada.
Lavoie H; Institute for Research in Immunology and Cancer, Laboratory of Intracellular Signaling, Université de Montréal, Quebec, Montreal, Canada.
Daou S; Center for Molecular, Cell and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Orlicky S; Center for Molecular, Cell and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Goullet de Rugy T; Center for Molecular, Cell and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Caldwell L; Center for Molecular, Cell and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Chan K; Center for Molecular, Cell and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Aman A; Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
Prakesch M; Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Poda G; Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
Mader P; Center for Molecular, Cell and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Wong C; Center for Molecular, Cell and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Maier S; Center for Molecular, Cell and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Kitaygorodsky J; Center for Molecular, Cell and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
Larsen B; Center for Molecular, Cell and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Colwill K; Center for Molecular, Cell and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Yin Z; Center for Molecular, Cell and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.; Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada.
Ceccarelli DF; Center for Molecular, Cell and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Batey RA; Department of Chemistry, University of Toronto, Toronto, Ontario, Canada.
Taipale M; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.; Donnelly Centre for Cellular and Biomolecular Research, Toronto, Ontario, Canada.
Kurinov I; Department of Chemistry and Chemical Biology, Cornell University, NE-CAT, Argonne, IL, USA.
Uehling D; Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Wrana J; Center for Molecular, Cell and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
Durocher D; Center for Molecular, Cell and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
Gingras AC; Center for Molecular, Cell and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
Al-Awar R; Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Therrien M; Institute for Research in Immunology and Cancer, Laboratory of Intracellular Signaling, Université de Montréal, Quebec, Montreal, Canada. .; Département de Pathologie et Biologie Cellulaire, University of Montréal, Quebec, Montreal, Canada. .
Sicheri F; Center for Molecular, Cell and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada. .; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada. .; Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada. .
Pokaż więcej
Źródło :
Nature chemical biology [Nat Chem Biol] 2020 Nov; Vol. 16 (11), pp. 1170-1178. Date of Electronic Publication: 2020 Aug 10.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Proto-Oncogene Proteins B-raf/*antagonists & inhibitors
Proto-Oncogene Proteins B-raf/*genetics
Thalidomide/*analogs & derivatives
Ubiquitin/*chemistry
Animals ; Apoptosis/drug effects ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Chimera/metabolism ; Drug Design ; Drug Resistance, Neoplasm ; Extracellular Signal-Regulated MAP Kinases/metabolism ; Female ; Gene Expression Regulation ; Humans ; MAP Kinase Signaling System ; Mice ; Mitogen-Activated Protein Kinase Kinases/metabolism ; Models, Molecular ; Molecular Structure ; Molecular Targeted Therapy ; Mutation ; Phosphorylation/drug effects ; Protein Binding ; Proteolysis ; Signal Transduction ; Structure-Activity Relationship ; Thalidomide/chemistry
Czasopismo naukowe
Tytuł :
Serum brain-derived neurotrophic factor (BDNF) concentration predicts polyneuropathy and overall survival in multiple myeloma patients.
Autorzy :
Szudy-Szczyrek A; Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland.
Mlak R; Department of Human Physiology, Medical University of Lublin, Lublin, Poland.
Bury-Kamińska M; Department of Clinical Psychology and Neuropsychology, Institute of Psychology, Maria Curie-Skłodowska University, Lublin, Poland.
Mielnik M; Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland.
Podgajna M; Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland.
Kuśmierczuk K; Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland.
Mazurek M; Department of Human Physiology, Medical University of Lublin, Lublin, Poland.
Homa-Mlak I; Department of Human Physiology, Medical University of Lublin, Lublin, Poland.
Szczyrek M; Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland.
Krawczyk J; Department of Haematology, University Hospital Galway, Galway, Republic of Ireland.; National University of Ireland, Galway, Republic of Ireland.
Małecka-Massalska T; Department of Human Physiology, Medical University of Lublin, Lublin, Poland.
Hus M; Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2020 Oct; Vol. 191 (1), pp. 77-89. Date of Electronic Publication: 2020 Jun 22.
Typ publikacji :
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Bortezomib*/administration & dosage
Bortezomib*/adverse effects
Multiple Myeloma*/blood
Multiple Myeloma*/drug therapy
Multiple Myeloma*/mortality
Polyneuropathies*/blood
Polyneuropathies*/chemically induced
Polyneuropathies*/mortality
Thalidomide*/administration & dosage
Thalidomide*/adverse effects
Biomarkers, Tumor/*blood
Brain-Derived Neurotrophic Factor/*blood
Adult ; Aged ; Aged, 80 and over ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Survival Rate
Czasopismo naukowe
Tytuł :
Psoriasis improvement and satisfaction in patients using a clobetasol spray and oral apremilast combination regimen: A pilot study.
Autorzy :
Wei C; Department of Dermatology, The George Washington School of Medicine and Health Sciences, Washington, DC; The George Washington School of Medicine and Health Sciences, Washington, DC.
Friedman AJ; Department of Dermatology, The George Washington School of Medicine and Health Sciences, Washington, DC.
Prussick RB; Department of Dermatology, The George Washington School of Medicine and Health Sciences, Washington, DC. Electronic address: .
Pokaż więcej
Źródło :
Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2020 Oct; Vol. 83 (4), pp. 1198-1200. Date of Electronic Publication: 2020 Feb 21.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
Clobetasol/*therapeutic use
Phosphodiesterase 4 Inhibitors/*therapeutic use
Psoriasis/*drug therapy
Thalidomide/*analogs & derivatives
Administration, Oral ; Aerosols ; Clobetasol/administration & dosage ; Drug Therapy, Combination ; Female ; Humans ; Male ; Patient Satisfaction ; Phosphodiesterase 4 Inhibitors/administration & dosage ; Pilot Projects ; Prospective Studies ; Thalidomide/administration & dosage ; Thalidomide/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Optimizing the Treatment of Moderate-to-Severe Psoriasis in Older Adults.
Autorzy :
Shary N; Department of Dermatology, State University of New York at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA.
Kalb RE; Department of Dermatology, State University of New York at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA. .
Pokaż więcej
Źródło :
Drugs & aging [Drugs Aging] 2020 Oct; Vol. 37 (10), pp. 715-723.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Anti-Inflammatory Agents/*therapeutic use
Antibodies, Monoclonal/*therapeutic use
Psoriasis/*drug therapy
Thalidomide/*analogs & derivatives
Aged ; Anti-Inflammatory Agents/administration & dosage ; Anti-Inflammatory Agents/adverse effects ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Comorbidity ; Drug Interactions ; Female ; Humans ; Middle Aged ; Psoriasis/epidemiology ; Psoriasis/immunology ; Severity of Illness Index ; Thalidomide/administration & dosage ; Thalidomide/adverse effects ; Thalidomide/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Role of thalidomide, senicapoc, and sodium butyrate in choroidal neovascularization.
Autorzy :
Lyzogubov V; Department of Ophthalmology, Jones Eye Institute, Pat & Willard Walker Eye Research Center and College of Medicine, University of Arkansas for Medical Sciences, 4301 West Markham St, Little Rock, AR, 72205, USA. Electronic address: .
Dasso M; Department of Ophthalmology, Jones Eye Institute, Pat & Willard Walker Eye Research Center and College of Medicine, University of Arkansas for Medical Sciences, 4301 West Markham St, Little Rock, AR, 72205, USA. Electronic address: .
Bora N; Department of Ophthalmology, Jones Eye Institute, Pat & Willard Walker Eye Research Center and College of Medicine, University of Arkansas for Medical Sciences, 4301 West Markham St, Little Rock, AR, 72205, USA. Electronic address: .
Bora PS; Department of Ophthalmology, Jones Eye Institute, Pat & Willard Walker Eye Research Center and College of Medicine, University of Arkansas for Medical Sciences, 4301 West Markham St, Little Rock, AR, 72205, USA. Electronic address: .
Pokaż więcej
Źródło :
Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2020 Sep 17; Vol. 530 (2), pp. 367-373. Date of Electronic Publication: 2020 Aug 13.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Acetamides/*therapeutic use
Angiogenesis Inhibitors/*therapeutic use
Butyric Acid/*therapeutic use
Choroidal Neovascularization/*drug therapy
Thalidomide/*therapeutic use
Trityl Compounds/*therapeutic use
Acetamides/pharmacology ; Angiogenesis Inhibitors/pharmacology ; Animals ; Butyric Acid/pharmacology ; Cell Line ; Cell Proliferation/drug effects ; Choroidal Neovascularization/pathology ; Disease Models, Animal ; Human Umbilical Vein Endothelial Cells ; Humans ; Male ; Mice, Inbred C57BL ; Thalidomide/pharmacology ; Trityl Compounds/pharmacology
Czasopismo naukowe
Tytuł :
Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide.
Autorzy :
Furihata H; Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan.
Yamanaka S; Proteo-Science Center, Ehime University, 3 Bunkyo-cho, Matsuyama, Ehime, 790-8577, Japan.
Honda T; Department of Nanopharmaceutical Sciences and Department of Life Science and Applied Chemistry, Nagoya Institute of Technology, Gokiso-cho, Showa-ku, Aichi, 466-8555, Japan.
Miyauchi Y; Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan.
Asano A; Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan.
Shibata N; Department of Nanopharmaceutical Sciences and Department of Life Science and Applied Chemistry, Nagoya Institute of Technology, Gokiso-cho, Showa-ku, Aichi, 466-8555, Japan.
Tanokura M; Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan. .
Sawasaki T; Proteo-Science Center, Ehime University, 3 Bunkyo-cho, Matsuyama, Ehime, 790-8577, Japan. .
Miyakawa T; Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2020 Sep 14; Vol. 11 (1), pp. 4578. Date of Electronic Publication: 2020 Sep 14.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunologic Factors/*chemistry
Immunologic Factors/*pharmacology
Thalidomide/*analogs & derivatives
Adaptor Proteins, Signal Transducing/chemistry ; Adaptor Proteins, Signal Transducing/metabolism ; Amino Acid Sequence ; HEK293 Cells ; Humans ; Protein Binding/drug effects ; Protein Domains ; Stereoisomerism ; Structural Homology, Protein ; Substrate Specificity ; Thalidomide/chemistry ; Thalidomide/pharmacology ; Transcription Factors/chemistry ; Transcription Factors/metabolism ; Ubiquitin-Protein Ligases
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies